Dynavax Technologies | DVAX - Operating Expenses


Dynavax Technologies reported $73.6M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
AbbVie USD -2.64B 12.35B Sep/2025
Adma Biologics USD 83.21M 4.02M Sep/2025
Amgen USD 5.13B 1.39B Sep/2025
AstraZeneca USD 16.69B 5.74B Sep/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 807.82M 259.3M Sep/2025
Bristol-Myers Squibb USD 18.55B 10.06B Sep/2025
Dynavax Technologies USD 73.6M 7.41M Sep/2025
Gilead Sciences USD 4.26B 95M Sep/2025
Glaxosmithkline GBP 7.77B 2.22B Sep/2025
Merck USD 10.72B 1.28B Sep/2025
Neurocrine Biosciences USD 555.6M 13.7M Sep/2025
Novartis USD 9.86B 115M Sep/2025
Pfizer USD 92.8B 82.47B Sep/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sarepta Therapeutics USD 462.23M 33.28M Sep/2025
TG Therapeutics USD 132.34M 26.04M Sep/2025
Vertex Pharmaceuticals USD 1.84B 27.1M Sep/2025